Profile cover photo
Profile photo
Aethlon Medical, Inc.
29 followers -
Aethlon Medical, Inc. (NASDAQ:AEMD) is creating innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions.
Aethlon Medical, Inc. (NASDAQ:AEMD) is creating innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions.

29 followers
About
Aethlon Medical, Inc.'s posts

Post has attachment
Aethlon Chairman and CEO Jim Joyce penned a note discussing Bill Gates address at the Munich Security Conference on the threat of bioterrorism and the fact that governments around the world are neither prepared nor equipped to respond to the threat of a genetically engineered virus used as a weapon. Mr. Joyce goes on to discuss the Hemopurifiers potential as a broad-spectrum countermeasure targeting bioterror, pandemic threats and other pathogens that are not well addressed with traditional drug or vaccine therapies. Read the full post here:

Post has attachment
Aethlon reported the results of a study that validated the ability of the Hemopurifier® to capture latent viral pathogens that are associated with increased mortality in immune-suppressed sepsis patients and also contribute to organ rejection in transplant patients. In the latent viral pathogen study, a 72% reduction of Herpes Simplex virus 1 (HSV1) from human blood serum was observed in six hours of Hemopurifier® application. Studies involving Epstein-Barr virus (EBV) and Cytomegalovirus (CMV) were also conducted, showing a reduction of 77% and 88%, respectively, during the six-hour applications. Read today's press release for additional study details:

Post has attachment
Aethlon Medical Announces Fiscal 2017 Third Quarter Results

Post has attachment
Former Detroit Lions running back Mel Farr had Stage 3 chronic traumatic encephalopathy (CTE) at the time of his death according to the Boston University's CTE Center.

Post has attachment
Aethlon today announced that it will host its Third Quarter Fiscal 2017 investor conference call and webcast on Friday, February 10, 2017 at 4:30 p.m. Eastern Time. The call and webcast will follow the release of fiscal 2017 third quarter results. Read today's press release for conference call details:

Post has attachment
Aethlon CEO James Joyce and Solomon Wilcots, NFL Analyst for CBS Sports, are in Houston raising awareness of CTE research and Exosome Science's upcoming study to develop a blood test. Listen to their feature on the Jose Rose Show here:

Post has attachment
Ahead of the super bowl, families affected by Chronic Traumatic Encephalopathy launched Faces of CTE, a collaboration dedicated to raising awareness and increasing brain donations.

Post has attachment
Aethlon CEO spoke on the Boomer and Carton Show with NFL Analyst Solomon Wilcots to discuss research on concussions, CTE and finding a blood test to detect CTE in the living.

Post has attachment
Researchers from Aethlon's diagnostic subsidiary, Exosome Sciences, Inc., announced plans to initiate a clinical study involving retired NFL players and a data-supported biomarker candidate to detect and monitor Chronic Traumatic Encephalopathy (CTE) in living individuals. The goal of the study will be to further validate a CTE biomarker candidate known as plasma exosomal tau, or a TauSome™. Read the press release for additional details on CTE, TauSome™ and the upcoming study.

Post has attachment
In a recent report, the Blue Ribbon Study Panel on Biodefense highlights how the U.S. is unprepared to fight dangerous biological incidents and the need for innovative solutions.
Wait while more posts are being loaded